185 related articles for article (PubMed ID: 24966967)
21. A systematic review of dual targeting in HER2-positive breast cancer.
Kümler I; Tuxen MK; Nielsen DL
Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
[TBL] [Abstract][Full Text] [Related]
22. Does HER2 immunoreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy?
Tsai YS; Tzai TS; Chow NH
Urol Int; 2007; 79(3):210-6. PubMed ID: 17940352
[TBL] [Abstract][Full Text] [Related]
23. Impact of p53, MIB-1 and PECAM-1 expression on the prognosis of urothelial carcinoma of the renal pelvis.
García-Tello A; Angulo JC; Andrés G; Ramón de Fata F; Sánchez-Chapado M; López JI
Actas Urol Esp; 2014 Oct; 38(8):506-14. PubMed ID: 24702909
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of Her2/neu overexpression in urothelial carcinomas.
Alexa A; Baderca F; Zăhoi DE; Lighezan R; Izvernariu D; Raica M
Rom J Morphol Embryol; 2010; 51(2):277-82. PubMed ID: 20495743
[TBL] [Abstract][Full Text] [Related]
25. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?
Gandour-Edwards R; Lara PN; Folkins AK; LaSalle JM; Beckett L; Li Y; Meyers FJ; DeVere-White R
Cancer; 2002 Sep; 95(5):1009-15. PubMed ID: 12209684
[TBL] [Abstract][Full Text] [Related]
26. EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features.
Guo S; Li X; Rohr J; Wang Y; Ma S; Chen P; Wang Z
Diagn Pathol; 2016 Apr; 11():41. PubMed ID: 27113214
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathologic study of 60 cases of urothelial neoplasms with inverted growth patterns: Reclassification by international consultation on urologic disease (ICUD) recommendations.
Bang H; Park H; Park S; Choi E; Cho MS; Sung SH; Choi SY; Cho YM; Jeong SU; Ro JY
Ann Diagn Pathol; 2020 Feb; 44():151433. PubMed ID: 31785538
[TBL] [Abstract][Full Text] [Related]
28. Neoplasms of the upper urinary tract: a review with focus on urothelial carcinoma of the pelvicalyceal system and aspects related to its diagnosis and reporting.
Gupta R; Paner GP; Amin MB
Adv Anat Pathol; 2008 May; 15(3):127-39. PubMed ID: 18434765
[TBL] [Abstract][Full Text] [Related]
29. The role of p95HER2 in trastuzumab resistance in breast cancer.
Ozkavruk Eliyatkin N; Aktas S; Ozgur H; Ercetin P; Kupelioglu A
J BUON; 2016; 21(2):382-9. PubMed ID: 27273948
[TBL] [Abstract][Full Text] [Related]
30. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
[TBL] [Abstract][Full Text] [Related]
31. Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer.
Gilcrease MZ; Woodward WA; Nicolas MM; Corley LJ; Fuller GN; Esteva FJ; Tucker SL; Buchholz TA
Am J Surg Pathol; 2009 May; 33(5):759-67. PubMed ID: 19252432
[TBL] [Abstract][Full Text] [Related]
32. Micropapillary variant of urothelial carcinoma in the upper urinary tract: a clinicopathologic study of 11 cases.
Guo CC; Tamboli P; Czerniak B
Arch Pathol Lab Med; 2009 Jan; 133(1):62-6. PubMed ID: 19123738
[TBL] [Abstract][Full Text] [Related]
33. Comparison of tyrosine kinase receptors HER2, EGFR, and VEGFR expression in micropapillary urothelial carcinoma with invasive urothelial carcinoma.
Li J; Jackson CL; Yang D; Noble L; Wheeler M; MacKenzie D; Adegun T; Amin A
Target Oncol; 2015 Sep; 10(3):355-63. PubMed ID: 25293577
[TBL] [Abstract][Full Text] [Related]
34. HER2 testing in gastric cancer: An update.
Abrahao-Machado LF; Scapulatempo-Neto C
World J Gastroenterol; 2016 May; 22(19):4619-25. PubMed ID: 27217694
[TBL] [Abstract][Full Text] [Related]
35. HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications.
Krüger S; Weitsch G; Büttner H; Matthiensen A; Böhmer T; Marquardt T; Sayk F; Feller AC; Böhle A
Int J Cancer; 2002 Dec; 102(5):514-8. PubMed ID: 12432555
[TBL] [Abstract][Full Text] [Related]
36. Long-term outcome of primary Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP) including PUNLMP with inverted growth.
Maxwell JP; Wang C; Wiebe N; Yilmaz A; Trpkov K
Diagn Pathol; 2015 Mar; 10():3. PubMed ID: 25886613
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
38. New HER2-positive targeting agents in clinical practice.
Tolaney S
Curr Oncol Rep; 2014; 16(1):359. PubMed ID: 24442625
[TBL] [Abstract][Full Text] [Related]
39. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors.
Niikura N; Liu J; Hayashi N; Mittendorf EA; Gong Y; Palla SL; Tokuda Y; Gonzalez-Angulo AM; Hortobagyi GN; Ueno NT
J Clin Oncol; 2012 Feb; 30(6):593-9. PubMed ID: 22124109
[TBL] [Abstract][Full Text] [Related]
40. Comparative effectiveness of neoadjuvant therapy for HER2-positive breast cancer: a network meta-analysis.
Nagayama A; Hayashida T; Jinno H; Takahashi M; Seki T; Matsumoto A; Murata T; Ashrafian H; Athanasiou T; Okabayashi K; Kitagawa Y
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25224562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
